vs
碧迪（BDX）与艾默生（EMR）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是艾默生的1.2倍（$5.3B vs $4.3B），艾默生净利率更高（13.9% vs 7.3%，领先6.6%），艾默生同比增速更快（4.1% vs -0.4%），艾默生自由现金流更多（$602.0M vs $549.0M），过去两年碧迪的营收复合增速更高（2.0% vs -0.3%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
艾默生是总部位于美国密苏里州圣路易斯的世界500强跨国企业，业务涵盖工业自动化设备、暖通控制系统、精密测量仪器的研发制造，同时面向工业、商业、消费级市场提供工程服务及对应软件工程解决方案。
BDX vs EMR — 直观对比
营收规模更大
BDX
是对方的1.2倍
$4.3B
营收增速更快
EMR
高出4.5%
-0.4%
净利率更高
EMR
高出6.6%
7.3%
自由现金流更多
EMR
多$53.0M
$549.0M
两年增速更快
BDX
近两年复合增速
-0.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $4.3B |
| 净利润 | $382.0M | $605.0M |
| 毛利率 | 45.9% | 53.2% |
| 营业利润率 | 10.5% | 17.8% |
| 净利率 | 7.3% | 13.9% |
| 营收同比 | -0.4% | 4.1% |
| 净利润同比 | 24.0% | 3.4% |
| 每股收益（稀释后） | $1.34 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXEMR
| Q4 25 | $5.3B | $4.3B | ||
| Q3 25 | $5.9B | $4.9B | ||
| Q2 25 | $5.5B | $4.6B | ||
| Q1 25 | $5.3B | $4.4B | ||
| Q4 24 | $5.2B | $4.2B | ||
| Q3 24 | $5.4B | $4.6B | ||
| Q2 24 | $5.0B | $4.4B | ||
| Q1 24 | $5.0B | $4.4B |
净利润BDXEMR
| Q4 25 | $382.0M | $605.0M | ||
| Q3 25 | $493.0M | $637.0M | ||
| Q2 25 | $574.0M | $586.0M | ||
| Q1 25 | $308.0M | $485.0M | ||
| Q4 24 | $303.0M | $585.0M | ||
| Q3 24 | $400.0M | $996.0M | ||
| Q2 24 | $487.0M | $329.0M | ||
| Q1 24 | $537.0M | $501.0M |
毛利率BDXEMR
| Q4 25 | 45.9% | 53.2% | ||
| Q3 25 | 47.5% | 51.9% | ||
| Q2 25 | 47.8% | 52.6% | ||
| Q1 25 | 42.8% | 53.5% | ||
| Q4 24 | 43.2% | 53.5% | ||
| Q3 24 | 45.7% | 51.3% | ||
| Q2 24 | 46.2% | 52.8% | ||
| Q1 24 | 45.7% | 52.2% |
营业利润率BDXEMR
| Q4 25 | 10.5% | 17.8% | ||
| Q3 25 | 11.8% | 16.4% | ||
| Q2 25 | 16.0% | 16.1% | ||
| Q1 25 | 10.4% | 14.2% | ||
| Q4 24 | 8.8% | 18.6% | ||
| Q3 24 | 11.4% | 14.7% | ||
| Q2 24 | 12.1% | 10.4% | ||
| Q1 24 | 14.5% | 16.2% |
净利率BDXEMR
| Q4 25 | 7.3% | 13.9% | ||
| Q3 25 | 8.4% | 13.1% | ||
| Q2 25 | 10.4% | 12.9% | ||
| Q1 25 | 5.8% | 10.9% | ||
| Q4 24 | 5.9% | 14.0% | ||
| Q3 24 | 7.4% | 21.6% | ||
| Q2 24 | 9.8% | 7.5% | ||
| Q1 24 | 10.6% | 11.4% |
每股收益（稀释后）BDXEMR
| Q4 25 | $1.34 | $1.07 | ||
| Q3 25 | $1.71 | $1.12 | ||
| Q2 25 | $2.00 | $1.04 | ||
| Q1 25 | $1.07 | $0.86 | ||
| Q4 24 | $1.04 | $1.02 | ||
| Q3 24 | $1.37 | $1.74 | ||
| Q2 24 | $1.68 | $0.57 | ||
| Q1 24 | $1.85 | $0.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | — |
| 总债务越低越好 | — | $7.6B |
| 股东权益账面价值 | $25.3B | $20.3B |
| 总资产 | $54.8B | $41.9B |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资BDXEMR
| Q4 25 | $740.0M | — | ||
| Q3 25 | $641.0M | — | ||
| Q2 25 | $735.0M | — | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $2.3B | — |
总债务BDXEMR
| Q4 25 | — | $7.6B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.3B | ||
| Q1 25 | — | $8.2B | ||
| Q4 24 | — | $6.6B | ||
| Q3 24 | — | $7.7B | ||
| Q2 24 | — | $7.1B | ||
| Q1 24 | — | $7.6B |
股东权益BDXEMR
| Q4 25 | $25.3B | $20.3B | ||
| Q3 25 | $25.4B | $20.3B | ||
| Q2 25 | $25.5B | $19.9B | ||
| Q1 25 | $25.2B | $19.2B | ||
| Q4 24 | $25.2B | $20.5B | ||
| Q3 24 | $25.9B | $21.6B | ||
| Q2 24 | $25.9B | $20.8B | ||
| Q1 24 | $25.6B | $20.9B |
总资产BDXEMR
| Q4 25 | $54.8B | $41.9B | ||
| Q3 25 | $55.3B | $42.0B | ||
| Q2 25 | $54.9B | $42.5B | ||
| Q1 25 | $54.5B | $42.0B | ||
| Q4 24 | $54.7B | $42.6B | ||
| Q3 24 | $57.3B | $44.2B | ||
| Q2 24 | $55.6B | $45.6B | ||
| Q1 24 | $54.2B | $46.4B |
负债/权益比BDXEMR
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.44× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.36× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $699.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $602.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 13.9% |
| 资本支出强度资本支出/营收 | 2.1% | 2.2% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.16× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $4.4B |
8季度趋势，按日历期对齐
经营现金流BDXEMR
| Q4 25 | $657.0M | $699.0M | ||
| Q3 25 | $1.4B | $3.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $164.0M | $241.0M | ||
| Q4 24 | $693.0M | $777.0M | ||
| Q3 24 | $1.2B | $3.3B | ||
| Q2 24 | $1.3B | $1.1B | ||
| Q1 24 | $514.0M | $743.0M |
自由现金流BDXEMR
| Q4 25 | $549.0M | $602.0M | ||
| Q3 25 | $1.0B | $2.7B | ||
| Q2 25 | $1.0B | $977.0M | ||
| Q1 25 | $35.0M | $154.0M | ||
| Q4 24 | $588.0M | $694.0M | ||
| Q3 24 | $882.0M | $2.9B | ||
| Q2 24 | $1.1B | $998.0M | ||
| Q1 24 | $380.0M | $661.0M |
自由现金流率BDXEMR
| Q4 25 | 10.5% | 13.9% | ||
| Q3 25 | 17.0% | 54.9% | ||
| Q2 25 | 19.0% | 21.5% | ||
| Q1 25 | 0.7% | 3.5% | ||
| Q4 24 | 11.4% | 16.6% | ||
| Q3 24 | 16.2% | 63.1% | ||
| Q2 24 | 22.4% | 22.8% | ||
| Q1 24 | 7.5% | 15.1% |
资本支出强度BDXEMR
| Q4 25 | 2.1% | 2.2% | ||
| Q3 25 | 6.0% | 8.9% | ||
| Q2 25 | 3.2% | 2.0% | ||
| Q1 25 | 2.4% | 2.0% | ||
| Q4 24 | 2.0% | 2.0% | ||
| Q3 24 | 5.4% | 9.1% | ||
| Q2 24 | 3.6% | 2.1% | ||
| Q1 24 | 2.7% | 1.9% |
现金转化率BDXEMR
| Q4 25 | 1.72× | 1.16× | ||
| Q3 25 | 2.75× | 4.86× | ||
| Q2 25 | 2.12× | 1.83× | ||
| Q1 25 | 0.53× | 0.50× | ||
| Q4 24 | 2.29× | 1.33× | ||
| Q3 24 | 2.94× | 3.35× | ||
| Q2 24 | 2.66× | 3.31× | ||
| Q1 24 | 0.96× | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
EMR
| Other | $1.8B | 41% |
| Software And Systems | $1.0B | 24% |
| Intelligent Devices | $996.0M | 23% |
| Safety And Productivity | $503.0M | 12% |
